Revolutionizing Pediatric Cancer Treatment: Autolus Therapeutics Unveils Promising Data from AUTO1-22 Trial at EBMT 49th Annual Meeting
Autolus Therapeutics Announces Data from AUTO1/22 Trial in Pediatric Acute Lymphoblastic Leukemia Data support utility of AUTO1/22 approach in preventing antigen evasion in pediatric B-ALL Complete responses observed in patients with CD19 negative disease No antigen negative relapse seen in responding patients LONDON, April 26, 2023 (GLOBE NEWSWIRE) — Autolus Therapeutics plc (Nasdaq: AUTL), a…